We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Alcon Inc | NYSE:ALC | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.73 | 0.92% | 80.30 | 80.51 | 79.80 | 80.14 | 399,236 | 20:36:11 |
From May 2022 to May 2024
By Chris Wack
Aerie Pharmaceuticals Inc. shares were up 34% to $14.91 in premarket trading after the company said it was being bought by Alcon AG for $15.25 a share.
The purchase price represents a premium of 37% to Aerie's last closing price and represents an equity value of $770 million.
The transaction was approved by the board of directors of each company.
Through the transaction, Alcon will add the commercial products Rocklatan netarsudil and latanoprost ophthalmic solution and Rhopressa netarsudil ophthalmic solution, as well as AR-15512, a Phase 3 product candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates.
The transaction is expected to be accretive to Alcon's core earnings per share in 2024.
The transaction is anticipated to close in the fourth quarter of 2022. Alcon intends to fund the acquisition through short-term and long-term debt.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
August 23, 2022 06:27 ET (10:27 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Alcon Chart |
1 Month Alcon Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
